Earlier this year, Google announced that it was developing a contact lens that would be capable of monitoring blood glucose levels. By monitoring a person’s glucose levels through their tears, and sending that information to a smartphone, the device promised to do away with tests that require regular blood samples and pinpricks. And now, a partnership has been announced between that will help see this project through to completion.
Alcon, the eye care division of Novartis – a Swiss multinational pharmaceutical company – recently joined Google’s project to commercialize “smart contact lens” technology. The project, which came out of the Google X blue-sky innovation arm of the company, aimed to utilize a “tiny wireless chip and miniaturized glucose sensor that are embedded between two layers of soft contact lens material,” in order to detect glucose levels present in tears.
At the time of the initial announcement in January, Google said its prototypes were able to take one glucose reading per second and that they was investigating ways for the device to act as an early warning system for the wearer should glucose levels become abnormal. All that was needed was a partner with the infrastructure and experience in the medical industry to see the prototypes put into production.
Under the terms of the new agreement, Google will license the technology to Alcon “for all ocular medical uses” and the two companies will collaborate to develop the lens and bring it to market. Novartis says that it sees Google’s advances in the miniaturization of electronics as complementary to its own expertise in pharmaceuticals and medical device. No doubt, the company also sees this as an opportunity to get in on the new trend of digitized, personalized medicine.
As Novartis said in a recent press release:
The agreement marries Google’s expertise in miniaturized electronics, low power chip design and microfabrication with Alcon’s expertise in physiology and visual performance of the eye, clinical development and evaluation, as well as commercialization of contact and intraocular lenses.
The transaction remains subject to anti-trust approvals, but assuming it goes through, Alcon hopes it will help to accelerate its product innovation. And with that, diabetics can look forward to yet another innovative device that simplifies the blood monitoring process and offers better early warning detection that can help reduce the risk of heart disease, stroke, kidney failure, foot ulcers, loss of vision, and coma.
Sources: gizmag.com, novartis.com